ClinicalTrials.gg
Active, not recruitingNCT05572229IFM2021-01Updated Sep 25, 2026

Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma

A Phase 2 interventional study of Teclistamab and Daratumumab in Multiple Myeloma, sponsored by University Hospital, Lille. Active, not recruiting at 22 sites in France. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by University Hospital, Lille · Phase 2, Interventional, and Treatment

How we know

Updated Sep 25, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 132 studies testing daratumumab in Multiple Myeloma — 21 open to participants now, 63 under way, 10 of them phase 3. daratumumab · Multiple Myeloma.

Planned enrollment
50th of 132
74 · median 50
Started
2023
with 8 others
Phase 2
73 of 132
7 open now
Primary completion
2027-06
later than 41 of 62 live
Registered
109th of 132
by date
Lead sponsor
3 of 132
University Hospital, Lille

Among the 132 studies testing daratumumab in Multiple Myeloma, this one is the 50th largest by planned enrollment, is one of 9 that started in 2023, is one of 73 in phase 2, reaches primary completion later than 41 of the 62 other live ones, and was the 109th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

21 of the 132 studies testing daratumumab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About daratumumab

daratumumab: first FDA approval 2015 (DARZALEX), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing daratumumab in Multiple Myeloma, or all of them as a file.
02

Study summary

The primary hypothesis of this study is that teclistamab SC in combination with daratumumab SC or lenalidomide will be safe and induce a high rate of VGPR or better in newly diagnosed multiple myeloma patients

This is an open-label, multicenter, non-comparative, 2-cohort, 2-stage with interruption of enrollment for an efficacy and safety interim analysis, interventional Phase 2 study evaluating the efficacy and safety of a combination with Tec-Dara (Cohort A) or Tec-Len (Cohort B) in patients with newly diagnosed multiple myeloma who are not eligible for SCT.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Newly diagnosed Multiple Myeloma
  • Elderly patients
  • Teclistamab
  • Daratumumab
  • Lenalidomide
  • Toxicity
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must be at least ≥65 years of age at the time of with documented multiple myeloma as defined by the criteria below:

    Multiple myeloma diagnosis according to IMWG diagnostic criteria

    at Screening as defined by any of the following:

    Serum monoclonal paraprotein (M-protein) level ³ 0.5 g/dL; or Urine M protein level ³ 200 mg/24 hours; or Serum Ig FLC ³ 10 mg/dL and abnormal serum Ig kappa/lambda FLC ratio

  2. Have an performance status score of 0-2
  3. Not considered for high-dose chemotherapy and SCT
  4. Have clinical laboratory values meeting the criteria during the Screening Phase.
  5. A male patient must wear a condom (with spermicidal foam/gel/film/cream/suppository) when engaging in any activity that allows for passage of ejaculate to another person during the study and for a minimum of 4 weeks after the last dose of lenalidomide or for a period of 3 months after the last dose of other study treatments, whichever occurs later. If the male patient's partner is a female of , she must also be practicing a highly effective method of . If the male patient is vasectomized, he still must wear a condom (with or without spermicidal foam/gel/film/cream/suppository), but his female partner is not required to use contraception.

7. A male patient must agree not to donate sperm for the purpose of reproduction during the study and for a minimum of 4 weeks after the last dose of lenalidomide or for period of 3 months after receiving the last dose of other study treatments, whichever occurs later.

8. Must sign an ICF (or their legally acceptable representative must sign in accordance with local requirements) indicating that the patient understands the purpose of, and procedures required for, the study and is willing to participate in the study.

9. Must be willing and able to adhere to the lifestyle restrictions specified in this protocol.

Exclusion criteria

Exclusion Criteria:

Medical Conditions

  1. CNS involvement or clinical signs of meningeal involvement of multiple myeloma. If either is suspected, negative whole brain MRI and lumbar cytology are required.
  2. Plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes), or primary light chain amyloidosis.
  3. Any ongoing myelodysplastic syndrome or B cell (other than multiple myeloma).
  4. Any history of malignancy, other than multiple myeloma, which is considered at high risk of recurrence requiring systemic therapy
  5. Any active malignancies (ie, progressing or requiring treatment change in the last 24 months) other than multiple myeloma.
  6. Stroke, , or seizure within 6 months prior to signing ICF.
  7. Presence of the a cardiac conditions.

    Tec-Dara-specific

  8. with a \<50% of predicted normal. Note that FEV1 testing is required for patients with known or suspected of having COPD or asthma and patients must be excluded if FEV1 \<50% of predicted normal.
  9. Moderate or severe persistent asthma within the past 2 years or uncontrolled asthma of any classification. Note that FEV1 testing is required for patients known or suspected asthma and patients must be excluded if FEV1 \<50% of predicted normal.

    Prior/Concomitant Therapy

  10. Radiotherapy within 14 days or focal radiation within 7 days.
  11. Received a cumulative dose of equivalent to ≥140 mg of prednisone within 14-days before the first dose of study drug (does not include pretreatment medications).
  12. Received a live, attenuated vaccine within 4 weeks before the first dose of study drug. Non-live or non-replicating vaccines authorized for emergency use (eg, COVID-19) are allowed.
  13. Any prior therapy for multiple myeloma or smoldering myeloma other than a short course of corticosteroids prior to signing ICF (not to exceed 40 mg of dexamethasone, or equivalent per day for a maximum of 4 days, total of 160 mg dexamethasone or equivalent).
  14. or life-threatening allergies, , or intolerance to any study drug or its .

    Diagnostic Assessments

  15. positive.
  16. infection.
  17. Active infection as measured by positive HCV-RNA testing. Other Exclusions
  18. Women of
  19. Patient had major surgery or had significant traumatic injury within 2 weeks prior to the start of administration of study treatment, or will not have fully recovered from surgery., or has major surgery planned during the time the patient is expected to be treated in the study or within 2 weeks after administration of the last dose of study treatment.
  20. Concurrent medical or psychiatric condition or disease that is likely to interfere with study procedures or results.
  21. Patient plans to father a child while enrolled in this study or within 3 months after the last dose of study intervention.
  22. Person under guardianship, trusteeship or deprived of freedom by a judicial or administrative decision.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
74 participants (estimated)

Study arms

  • Experimental
    Tec-Dara

    For patients assigned to cohort A (Tec-Dara) patients will receive Tec-Dara until documented PD or unacceptable toxicity

    Drug: Teclistamab · Drug: Daratumumab

  • Experimental
    Tec-Len

    For patients assigned to cohort B (Tec-Len) patients will receive Tec-Len until documented PD or unacceptable toxicity

    Drug: Teclistamab · Drug: Lenalidomide

Interventions

  • Teclistamab will be administered via a subcutaneous injection (SC)

    Also known as: JNJ-64007957

  • Daratumumab will be administered via a subcutaneous injection (SC)

  • Lenalidomide will be administered orally

06

What researchers measure

Primary outcomes

  1. Rate of very good partial response (VGPR) or better according to the IMWG criteria in patients with newly diagnosed multiple myeloma after 4 cycles of treatment with Tec-Dara or Tec-Len

    Time frame: At the end of 4 th cycle (each cycle is 28 days), an average 4 months

Secondary outcomes

  1. Treatment-emergent adverse events according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE, Version 5.0).

    Time frame: From date of randomization until the date of first documented progression,assessed up to 5 years

  2. Overall response rate(PR or better) as defined by the IMWG response criteria

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years

  3. Very good partial response or better, defined as VGPR or CR according to the IMWG criteria at the time of data cutoff

    Time frame: TFrom date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years

  4. Complete response or better, defined as negative immunofixation of serum and urine, and disappearance of any soft tissue plasmacytomas, and <5% plasma cells in bone marrow*

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years

  5. Time to response

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years

  6. Duration of response

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years

  7. Time from randomization to discontinuation of therapy for any reason including death, progression or toxicity

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years

  8. Overall survival time

    OS, measured from the date of the first dose of study treatment to the date of the patient's death. If the patient is alive or the vital status is unknown at last contact, then the patient's data will be censored at the date the patient was last known to be alive

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years

  9. TTTF, defined as the time from the date of the first dose of study treatment to discontinuation of therapy for any reason including death, progression, toxicity

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years

  10. TTNT, defined as the time from date of the first dose of study treatment to the start of the next-line treatmentTime-to-next treatment

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years

  11. Rate of minimal residual disease (MRD)-negativity (at level of 10-5 and 10-6 by NGS) at 6 months

    Time frame: at 6 months

  12. Rate of Sustained MRD-negativity-(at level of 10-5 and 10-6 by NGS)

    Time frame: at 18 months (12 months after the initial MRD time point).

07

Study locations

22 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Jun 2027, 42 months after the start.

Of 411 non-industry phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 42 months is below that.

Counting every sponsor, half of 504 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Apr 2026 → Jun 2027 and completion Sep 2030 → Sep 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2022
First posted
Oct 7, 2022
StartActual
Dec 21, 2023
Primary completionEst.
Jun 2027was Apr 2026
CompletionEst.
Sep 2032was Sep 2030
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Sep 25, 2026
Sites
7 sites removed
Show 7 removed
  • Aphp Hopital Avicenne · Bobigny, France
  • Ch de Dunkerque · Dunkirk, France
  • Hopital E. Muller- Ghrmsa · Mulhouse, France
  • Aphp - Hopital Saint Antoine · Paris, France
  • Aphp - Hopital Saint Louis · Paris, France
  • Chu de Reims · Reims, France
  • Chu Pontchaillou · Rennes, France
Sep 25, 2026
Primary completion
Apr 2026→Jun 2027
Sep 25, 2026
Study completion
Sep 2030→Sep 2032
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Recruiting→Active, not recruiting
    7 sites removed
    Show 7 removed
    • Aphp Hopital Avicenne · Bobigny, France
    • Ch de Dunkerque · Dunkirk, France
    • Hopital E. Muller- Ghrmsa · Mulhouse, France
    • Aphp - Hopital Saint Antoine · Paris, France
    • Aphp - Hopital Saint Louis · Paris, France
    • Chu de Reims · Reims, France
    • Chu Pontchaillou · Rennes, France
    Primary completion Apr 2026→Jun 2027
    Study completion Sep 2030→Sep 2032
    + 3 other changes: verification date, design details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05572229
Responsible party
Sponsor
First posted
Oct 7, 2022
Start date
Dec 21, 2023
Primary completion
Jun 2027 (estimated)
Completion
Sep 2032 (estimated)
Last update
Sep 25, 2026

Study contacts

Salomon MANIER, MD
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Daratumumab · Lenalidomide

Start the discussion